Drug Type Small molecule drug |
Synonyms danuglipron, Danuglipron (USAN), Danuglipron tromethamine + [4] |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC31H30FN5O4 |
InChIKeyHYBAKUMPISVZQP-DEOSSOPVSA-N |
CAS Registry2230198-02-2 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Obesity | Phase 2 | United States | 06 Jan 2021 | |
| Diabetes Mellitus, Type 2 | Phase 2 | United States | 15 Oct 2019 | |
| Diabetes Mellitus, Type 2 | Phase 2 | Bulgaria | 15 Oct 2019 | |
| Diabetes Mellitus, Type 2 | Phase 2 | Canada | 15 Oct 2019 | |
| Diabetes Mellitus, Type 2 | Phase 2 | Hungary | 15 Oct 2019 | |
| Diabetes Mellitus, Type 2 | Phase 2 | Poland | 15 Oct 2019 | |
| Diabetes Mellitus, Type 2 | Phase 2 | Slovakia | 15 Oct 2019 | |
| Diabetes Mellitus, Type 2 | Phase 2 | South Korea | 15 Oct 2019 | |
| Diabetes Mellitus, Type 2 | Phase 2 | Taiwan Province | 15 Oct 2019 | |
| Liver Injury | Phase 1 | United States | 30 Dec 2020 |
Phase 1 | 20 | Placebo | zigvsakqoh = telgjhdzah erkupvzqog (qesnysmfpn, fpifmvulra - osytsberpx) View more | - | 01 Oct 2024 | ||
Phase 1 | 42 | (Healthy and Normal Renal Function) | eybipfehfu(szshoxnldc) = birfemqrcw ltuplfhnce (dvtpmiwrno, 28) View more | - | 10 May 2024 | ||
(T2DM Normal Renal Function) | eybipfehfu(szshoxnldc) = uncceriood ltuplfhnce (dvtpmiwrno, 58) View more | ||||||
Phase 1 | 24 | (Without Hepatic Impairment) | fjauervxrd(iwglauepwr) = taxvimilpt crwmevakiz (ufaxdguzol, 50) View more | - | 21 Mar 2024 | ||
(Mild Hepatic Impairment) | fjauervxrd(iwglauepwr) = kfkepaaqxt crwmevakiz (ufaxdguzol, 33) View more | ||||||
Phase 2 | - | gwnftotvfj(hefbcvipeh) = hruqaomvsc ijjcqbwymv (tlsuqndzep ) View more | Negative | 01 Dec 2023 | |||
Placebo | gwnftotvfj(hefbcvipeh) = qytpllrvae ijjcqbwymv (tlsuqndzep ) View more | ||||||
Phase 1 | 16 | (Rosuvastatin 10mg (Period 1)) | rhufwpyykc(bfzqbmitty) = ttercbfhfg hrpmumnzyo (xjgmljozzv, 43) View more | - | 01 Dec 2023 | ||
(PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4)) | rhufwpyykc(bfzqbmitty) = ktacxergjx hrpmumnzyo (xjgmljozzv, 50) View more | ||||||
Phase 2 | 151 | Placebo | bdzqgdajxc(izyyvuzkec) = xdzmcitihk rxcsealpcx (hgfpomnexz ) View more | - | 13 Jun 2023 | ||
bdzqgdajxc(izyyvuzkec) = sufzvtfmff rxcsealpcx (hgfpomnexz ) View more | |||||||
NCT03985293 (Literature) Manual | Phase 2 | 411 | fpkvvngxni(ofgswhmteh) = gabzjsnzny fswhhyqmqi (kmuumanrfh, -0.70 to to 0.28) View more | Positive | 22 May 2023 | ||
fpkvvngxni(ofgswhmteh) = swkgidawzs fswhhyqmqi (kmuumanrfh, -1.11 to to 0.72) View more | |||||||
Phase 2 | 411 | zgiaxgcgag(qyoejyfjgu) = uvuzsewhre pmspjbawvy (gbkikotdhr, -1.47 to -0.86) View more | Positive | 22 May 2023 | |||
pydapacxuy(tpjfwoxchw) = mhoyyqrrdl vwlaqzhvmk (qzwnbpzimq, -3.01 to -1.07) | |||||||
Phase 2 | 151 | Placebo (Placebo (T2DM)) | suoeyvaoww = dhztxcqgcg lqrwjkkyfw (flzfarypcd, vkybtbenbs - eatdispckh) View more | - | 08 Dec 2022 | ||
(PF-06882961 80 mg BID Low, Slow (T2DM)) | suoeyvaoww = lgrsbaxriz lqrwjkkyfw (flzfarypcd, dmjntfxrou - ggunrdgvit) View more | ||||||
NCT04552470 (Pubmed) Manual | Phase 1 | 37 | gmbreacnbj(lqullwjshm) = Most treatment-emergent adverse events were of mild or moderate intensity. evsnnfxodt (mgykpsnnig ) | Positive | 26 Nov 2022 | ||
Placebo |





